AGENT™
Paclitaxel Coated-PTCA Balloon Catheter
![](https://www.bostonscientific.com/en-IN/products/balloons-drug-coated/agent/clinical-data/_jcr_content/maincontent-par/image_1.img.Agent-clinical%20-results-English.png)
Background
- Treatment of patients with in-stent restenosis (ISR) is an important clinical problem occurring in approximately 10% of PCI patients in real-world practice
- ISR is thought to result from aggressive neointimal proliferation or neoatherosclerosis
- Currently, drug-eluting stents and drug-coated balloons (DCB) are used to treat ISR
- DCB’s rapidly transfer the anti-proliferative drug, Paclitaxel, to the arterial vessel wall without adding another metal layer
![](https://www.bostonscientific.com/en-IN/products/balloons-drug-coated/agent/clinical-data/_jcr_content/maincontent-par/image_0.img.agent_graph_940x479_eu.jpg)